The goal of M²OLIE in the third and final funding phase is to complete the basic process established in the second funding phase with the aim of creating a comprehensive M²OLIE closed-loop process for the diagnosis and treatment of patients with oligometastases within a limited period of time. To ensure the holistic design of this process, four modules were introduced in the third funding phase, which can be flexibly combined in the future for different procedures and applications in other indications.
The process begins with patient admission, where the TEDIAS system will be integrated into the closed-loop process in the future. The fully digital and comprehensive process management system, the M²OLIE cockpit, guides the physicians through the various process steps.
The Operational Platform module is designed to connect all subcomponents of the M²OLIE closed-loop process to the cockpit and transfer them into the real clinical process.
The Interventional Platform module creates an intervention environment that significantly increases efficiency and precision at the diagnostic, therapeutic, and organizational levels through a higher degree of digitization and automation. When analyzing the biopsy, the Laboratory module will focus on the diagnostic and therapeutic addressing of tumor heterogeneity in order to achieve a complete, highly efficient, and partially automated characterization of tumor foci. The Tumor Board module aims to establish an ad hoc and asynchronous tumor board that can be convened and conducted using a mobile app and in which the guidelines are already integrated.
The establishment of the processes forms the basis for transferring the results to the planned M²OLIE clinic as an important pillar of the continuation strategy. In addition, the declared goal of all M²OLIE partners involved is to transfer the entire process or individual modules to other clinics so that tumor patients elsewhere can also benefit from this revolutionary diagnosis and treatment process.
